Petrovax Pharm announced the start of supplies of the quadrivalent vaccine for influenza prevention, Grippol® Quadrivalent. The total supply of the vaccine for Russian and foreign markets in 2022 will amount to more than 2.5 million doses.

Grippol® Quadrivalent vaccine was registered in Russia in 2018, the product is manufactured in Russia with the use of technology of a full manufacturing cycle of the finished dosage form (FDF) in accordance with GMP standards at the company’s own production complex. This influenza vaccine protects against 4 strains: 2 type A viruses (H1N1 and H3N2) and type B virus of 2 lines (B/Yamagata + B/Victoria). The azoximer bromide adjuvant, which is included in the composition of the vaccine, reduces the amount of antigens in the vaccine by three times and provides a pronounced humoral and cellular immune response, which is confirmed by scientific publications in the international peer-reviewed journals Frontiers in Immunology, Vaccine and others.

Grippol® Quadrivalent was developed according to the technology for the manufacture of the Grippol ® family vaccines, which are included in the state immunization programs in a number of countries, have a broad evidence base and have been used for many years. The creation and supply of the vaccine is in line with the implementation of the National Strategy for the Development of Immunoprophylaxis of Infectious Diseases for the period up to 2035, within the framework of which Russia approved a plan for the transition to the use of quadrivalent vaccines for influenza prevention for the period 2021-2025.

Mikhail Grubman, Managing Director of Petrovax Pharm biotechnology business, said:

Maintaining and strengthening the immunity of citizens is one of the key activities of the company. Supplies of the modern Grippol® Quadrivalent vaccine not only open up additional opportunities for protecting Russian patients from the influenza virus, but also expand the company’s export potential.

Since 2012, quadrivalent vaccines 8 have been recommended by WHO as being the most effective against influenza 9 . All influenza vaccines used for immunization in the United States in recent years, including those used in the pediatric segment, are quadrivalent. Most EU countries also use predominantly quadrivalent vaccines

According to experts, vaccination should take place 2-3 weeks before the increase in the incidence of influenza, the most suitable period for vaccination is from September to November. During the COVID-19 pandemic, influenza vaccination is part of the prevention of seasonal respiratory viral infections and it reduces the risk of infection and severe illness.

Petrovax is the largest exporter of influenza vaccines 13 , the company has been supplying the trivalent Grippol® Plus vaccine to the Russian and foreign markets for over 14 years, and this year its supply will exceed 12.5 million doses.